These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3524471)

  • 41. Intralesional interferon-alpha therapy in advanced malignant melanoma.
    von Wussow P; Block B; Hartmann F; Deicher H
    Cancer; 1988 Mar; 61(6):1071-4. PubMed ID: 3342367
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intralesional interferon in the treatment of early mycosis fungoides.
    Wolff JM; Zitelli JA; Rabin BS; Smiles KA; Abell E
    J Am Acad Dermatol; 1985 Oct; 13(4):604-12. PubMed ID: 2934438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevention of experimental coronavirus colds with intranasal alpha-2b interferon.
    Turner RB; Felton A; Kosak K; Kelsey DK; Meschievitz CK
    J Infect Dis; 1986 Sep; 154(3):443-7. PubMed ID: 3016111
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intranasal interferon (rIFN-alpha A, Ro 22-8181) for contact prophylaxis against common cold: a randomized, double-blind and placebo-controlled field study.
    Herzog C; Berger R; Fernex M; Friesecke K; Havas L; Just M; Dubach UC
    Antiviral Res; 1986 May; 6(3):171-6. PubMed ID: 3524441
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A retrospective study of the effect of long-term topical application of retinaldehyde (0.05%) on the development of actinic keratosis.
    Campanelli A; Naldi L
    Dermatology; 2002; 205(2):146-52. PubMed ID: 12218230
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.
    Camenga DL; Johnson KP; Alter M; Engelhardt CD; Fishman PS; Greenstein JI; Haley AS; Hirsch RL; Kleiner JE; Kofie VY
    Arch Neurol; 1986 Dec; 43(12):1239-46. PubMed ID: 3535752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection.
    Monto AS; Shope TC; Schwartz SA; Albrecht JK
    J Infect Dis; 1986 Jul; 154(1):128-33. PubMed ID: 3011917
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recombinant alpha-2a interferon (alpha-IFN) in the treatment of essential thrombocythaemia. Preliminary report.
    Gugliotta L; Macchi S; Catani L; Chetti L; Mattioli Belmonte M; Guarini A; Criscuolo D; Tura S
    Haematologica; 1987; 72(3):277-9. PubMed ID: 3114099
    [No Abstract]   [Full Text] [Related]  

  • 49. High incidence and regression rates of solar keratoses in a queensland community.
    Frost C; Williams G; Green A
    J Invest Dermatol; 2000 Aug; 115(2):273-7. PubMed ID: 10951246
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma.
    Yung WK; Castellanos AM; Van Tassel P; Moser RP; Marcus SG
    J Neurooncol; 1990 Aug; 9(1):29-34. PubMed ID: 2082958
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inflammation of actinic keratoses from systemic chemotherapy.
    Johnson TM; Rapini RP; Duvic M
    J Am Acad Dermatol; 1987 Aug; 17(2 Pt 1):192-7. PubMed ID: 3624557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intranasal interferon alpha 2 for prevention of rhinovirus infection and illness.
    Hayden FG; Gwaltney JM
    J Infect Dis; 1983 Sep; 148(3):543-50. PubMed ID: 6311914
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Response of warts in epidermodysplasia verruciformis to treatment with systemic and intralesional alpha interferon.
    Androphy EJ; Dvoretzky I; Maluish AE; Wallace HJ; Lowy DR
    J Am Acad Dermatol; 1984 Aug; 11(2 Pt 1):197-202. PubMed ID: 6384282
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ingested type I interferon: state of the art as treatment for autoimmunity.
    Brod SA
    Exp Biol Med (Maywood); 2002 Dec; 227(11):981-8. PubMed ID: 12486207
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preliminary observation on the clinical tolerance of interferon-beta in cancer patients.
    Liberati AM; Puxeddu A; Biscottini B; Allegra A; Pennacchi M; Bertoni P; Pecci A; Ballatori E; Grignani F
    Tumori; 1985 Feb; 71(1):45-9. PubMed ID: 3885523
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of dose-intensive oral vitamin A in subjects with sun-damaged skin.
    Alberts D; Ranger-Moore J; Einspahr J; Saboda K; Bozzo P; Liu Y; Xu XC; Lotan R; Warneke J; Salasche S; Stratton S; Levine N; Goldman R; Islas M; Duckett L; Thompson D; Bartels P; Foote J
    Clin Cancer Res; 2004 Mar; 10(6):1875-80. PubMed ID: 15041701
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of recombinant interferon-alpha 2 following intralesional administration in malignant glioma patients.
    Maleci A; Antonelli G; Guidetti B; Dianzani F
    J Interferon Res; 1987 Feb; 7(1):107-9. PubMed ID: 3585078
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Spontaneous remission of solar keratoses: the case for conservative management.
    Marks R; Foley P; Goodman G; Hage BH; Selwood TS
    Br J Dermatol; 1986 Dec; 115(6):649-55. PubMed ID: 3801305
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of cancer patients receiving interferon alfa-2a.
    Gauci L
    Int J Cancer Suppl; 1987; 1():21-30. PubMed ID: 3476474
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiviral effect of bacterially produced human interferon (Hu-IFN alpha 2) against experimental vaccinia infection in calves.
    Werenne J; Vanden Broecke C; Schwers A; Goossens A; Bugyaki L; Maenhoudt M; Pastoret PP
    J Interferon Res; 1985; 5(1):129-36. PubMed ID: 3989335
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.